What is NAUT's market cap?

$291.68M, based on the Nov 4 close of $2.29.

Does Nautilus Biotechnolgy pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NAUT is sold short?

5.6M shares, 10.4% of float, as of Oct 15, 2026.

What sector is NAUT in?

Healthcare, in the Lab Analytical Instruments industry.

NASDAQ · NAUTHealthcareLab Analytical Instruments

Nautilus Biotechnolgy, Inc. Common Stock (NAUT)

$2.29−2.55%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$2.29▲ 44.03% in range

Nov 4, 2025Low $0.85 · High $3.95Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Nautilus Biotechnolgy closed at $2.29 on Nov 4, down 2.55%, 42.0% below its 52-week closing high. Volume of 6.5M shares was 0.59× its 20-day average (below normal).

Split-adjusted performance: +29.4% over one month, -22.1% over six months, +23.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $234K, with a net margin of -6682.1%.

Short interest was 5.6M shares at the Oct 15 settlement, down 2.6% from the prior report (10.4% of float, 1.0 days to cover).

Market cap$291.7M127.4M shares

Revenue · quarter$234.0K—

Diluted EPS$-0.12—

P/E · TTM—P/S 687.9×

Net margin-6,682.1%Gross 89.7%

Dividend yieldNone

52-week range0.85 – 3.95−42.0% from high

Volume6.5M0.59× 20-day avg

Volatility · 60d156.2%Annualised

Short % of float10.4%1.0 days to cover

Net cash$86.6MCash $86.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −28.7%1M +29.4%3M +158.4%6M −22.1%YTD +17.4%1Y +23.8%3Y −2.1%5Y −56.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum15

Revenue growth—

Net margin5

Value (low P/E)—

Size38

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →

Shares short5.6M−2.6% vs prior

Days to cover1.0Settled Oct 15

% of float10.4%

Short vol. 10d43.6%of daily volume

Closest peers by size in Lab Analytical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NAUTNautilus Biotechnolgy	$2.29	−2.55%	−22.1%	—	−6682.1%	—	$291.7M
MASS908 Devices	$11.07	+3.75%	+37.3%	+23.3%	−74.0%	—	$457.6M	Compare
QTRXQuanterix	$3.04	+3.40%	−7.6%	+34.4%	−148.7%	—	$143.8M	Compare
CTKBCytek Biosciences	$5.88	−1.34%	+19.0%	+5.6%	−25.3%	—	$764.3M	Compare
PACBPacific Biosciences of California	$2.55	+4.51%	+49.1%	−1.9%	−114.7%	—	$792.6M	Compare
SEERSeer	$1.70	−1.73%	−10.1%	−23.4%	−544.8%	—	$94.1M	Compare
ALMRAlamar Biosciences	$27.39	−9.36%	—	—	−44.9%	—	$1.90B	Compare
HBIOHarvard Bioscience	$8.61	−0.69%	+18.9%	+11.1%	−12.8%	—	$39.2M	Compare
PRPOPrecipio	$19.57	+5.10%	−34.7%	+24.7%	−3.1%	—	$35.0M	Compare

News about Nautilus Biotechnolgy

All news →

Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS ConsortiumGlobeNewswire Inc. · Oct 27, 2026▲ Positive Nautilus Biotechnology Reports Third Quarter 2026 Financial ResultsGlobeNewswire Inc. · Oct 27, 2026▲ Positive Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026GlobeNewswire Inc. · Oct 15, 2026Neutral

Quick answers

What does Nautilus Biotechnolgy do?: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
What is NAUT's market cap?: $291.68M, based on the Nov 4 close of $2.29.
Does Nautilus Biotechnolgy pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NAUT is sold short?: 5.6M shares, 10.4% of float, as of Oct 15, 2026.
What sector is NAUT in?: Healthcare, in the Lab Analytical Instruments industry.

About Nautilus Biotechnolgy

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

HQ: Seattle, WA130 employeesListed Jun 10, 2021nautilus.bio

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology